Summary & Overview
HCPCS G2071: Buprenorphine Implant Removal, MAT Weekly Bundle
HCPCS Level II code G2071 identifies a weekly bundled medication assisted treatment (MAT) service for buprenorphine implant removal provided by a Medicare-enrolled opioid treatment program. The bundle combines dispensing or administration of medication with behavioral health components—substance use counseling, individual and group therapy—and includes toxicology testing when performed. This code matters nationally as policymakers and payers increasingly focus on standardized billing for integrated MAT services and on improving access to evidence-based opioid use disorder care.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and operational scope of the code, typical sites of service, and which payers cover or recognize this service in the national analysis. The publication also outlines benchmarks and policy-relevant updates tied to bundled MAT billing, highlights clinical context for buprenorphine implant removal within OTP settings, and points to areas where data are limited or require further clarification.
The report is written for national audiences including payers, providers, and health policy stakeholders seeking clarity on billing and coding for integrated MAT services centered on buprenorphine implant removal.
Billing Code Overview
HCPCS Level II code G2071 describes a weekly bundled service for medication assisted treatment (MAT) related to buprenorphine implant removal when provided by a Medicare-enrolled opioid treatment program. The bundle includes dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed.
-
Service type: Medication assisted treatment bundle for buprenorphine implant removal
-
Typical site of service: Opioid treatment program (OTP) enrolled with Medicare
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with opioid use disorder presents to a Medicare-enrolled opioid treatment program for removal of a subdermal buprenorphine implant after the therapeutic course is completed or if complications require explantation. The visit is performed at an outpatient opioid treatment program facility with a multidisciplinary team. The typical clinical workflow includes intake assessment by a nurse or counselor, focused history and physical by a qualified clinician to assess implant status and removal indication, informed consent and procedure explanation, local anesthesia and implant removal by a trained clinician, brief wound care and dressing application, post-procedure observation for bleeding or adverse reaction, and coordination of follow-up substance use counseling, individual or group therapy sessions, medication dispensing if indicated, and urine toxicology testing. Documentation includes procedure note with implant lot/identification, informed consent, anesthesia used, specimens if any, counseling content, and toxicology results when performed. Billing uses the weekly bundled code G2071 when the opioid treatment program provides the bundle of services including dispensing/administration, counseling (individual and/or group), and toxicology testing during the week of the implant removal.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than typically required for (document rationale and submit supporting records). |